1Folkman J.What is the evidence that tumors are angiogenesis dependent[J]? J Natl Cancer Inst,1990,82:4-6.
2Napoleone F.Vascular endothelial growth factor as a target for anticancer therapy[J].Oncologist,2004,9(suppl 1):2-10.
3Jain RK.Delivery of novel therapeutic agents in tumors:physiological barriers and strategies[J].J Natl Cancer Inst,1989,81:570-576.
4Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307:58-62.
5Lee CG,Heijn M,di Tomaso E,et al.Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions[J].Cancer Res,2000,60:5565-5570.
6Kim KJ,Li B,Winer J,et al.Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo[J].Nature,1993,362:841-844.
7Warren RS,Yaun H,Matli MR.Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis[J].J Clin Invest,1995,95:1789-1797.
8Sweeney CJ,Miller KD,Sissons SE,et al.The antiangiogenic property of docetaxel is synergistic with a recombinant humanzed monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors[J].Cancer Res,2001,61:3369-3372.
9Wedam SB,Low JA.Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J].J Clin Oncol,2006,24(5):769-777.
10Hope S.Rugo.Bevacizumab in the treatment of breast cancer:rationale and current data[J].Oncologist,2004,9(suppl 1):43-49.
